Detalhe da pesquisa
1.
Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024.
Euro Surveill
; 29(10)2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38456217
2.
Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Delta and Omicron Infection and Infectiousness Within Households in the Netherlands Between July 2021 and August 2022.
J Infect Dis
; 228(4): 431-438, 2023 08 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37093964
3.
Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022.
Euro Surveill
; 28(7)2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36795500
4.
Is patient exposure preapproval and postapproval a determinant of the timing and frequency of occurrence of safety issues?
Pharmacoepidemiol Drug Saf
; 27(2): 168-173, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29278866
5.
Assessment of hybrid population immunity to SARS-CoV-2 following breakthrough infections of distinct SARS-CoV-2 variants by the detection of antibodies to nucleoprotein.
Sci Rep
; 13(1): 18394, 2023 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37884642
6.
Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study.
Int J Infect Dis
; 133: 36-42, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37086863
7.
Effects of COVID-19 vaccination and previous infection on Omicron SARS-CoV-2 infection and relation with serology.
Nat Commun
; 14(1): 4793, 2023 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37558656
8.
Introduction or Discontinuation of Additional Risk Minimisation Measures During the Life Cycle of Medicines in Europe.
Drug Saf
; 44(1): 63-72, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33000427
9.
Dissemination of Direct Healthcare Professional Communications on Medication Errors for Medicinal Products in the EU: An Explorative Study on Relevant Factors.
Drug Saf
; 44(1): 73-82, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33355904
10.
Description of the Risk Management of Medication Errors for Centrally Authorised Products in the European Union.
Drug Saf
; 43(1): 45-55, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31617081
11.
Exploratory Study of Signals for Asthma Drugs in Children, Using the EudraVigilance Database of Spontaneous Reports.
Drug Saf
; 43(1): 7-16, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31617080
12.
Fatal outcomes following immunization errors as reported to the EudraVigilance: A case series.
Vaccine
; 38(15): 3086-3095, 2020 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32147297
13.
Spontaneous reports of vaccination errors in the European regulatory database EudraVigilance: A descriptive study.
Vaccine
; 36(52): 7956-7964, 2018 12 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-30416019